Rocket Doctor AI Inc. has signed a definitive share purchase agreement to acquire all issued and outstanding securities of Alea Health Holdings Ltd. The agreement, dated November 19, 2025, follows an earlier announcement in January and involves the company, Alea, and Alea’s ordinary shareholders. Upon completion, the proposed transaction will give Rocket Doctor AI full ownership of Alea, pending customary regulatory and shareholder approvals.
Advancing AI Driven Mental Health Solutions
Acquiring Alea is designed to accelerate Rocket Doctor AI’s ambition to become a leading player in AI-powered health technology, with a particular emphasis on mental health. Alea operates a proprietary online therapy platform that uses conversational AI and voice technology to streamline patient intake, follow-up, and continuous support through a 24/7 AI mental health coach. By integrating this platform with Rocket Doctor AI’s Global Library of Medicine, the company aims to build a unified clinical decision and support environment that expands its mental health capabilities and reinforces its advocacy for conversational AI in care delivery over the coming decade.
Expansion into the Middle East and GCC
The transaction also serves as a strategic entry point into the Middle East, anchored by Alea’s presence in the United Arab Emirates. With the Gulf Cooperation Council expected to deploy up to 170 billion dollars into AI-enabled healthcare by 2030, Alea’s existing relationships and opportunities provide Rocket Doctor AI with early access to a high-growth market. This regional foothold is intended to support deeper partnerships in the GCC and advance the company’s efforts to integrate mental health services with primary care, complementing its existing digital health platform and marketplace.
Strengthening Healthtech Expertise and Leadership
Alea’s team brings additional depth to Rocket Doctor AI’s technical and operational bench. Led by chief executive officer Richard Dallala and chief data and operations officer Marco Bertetti, the group contributes more than three decades of combined international experience across AI, machine learning, SaaS, cloud infrastructure, and data science. Their background in mental health services, telemedicine, and patient intake software is expected to immediately enhance Rocket Doctor AI’s ability to design, deploy, and scale AI-driven healthcare solutions for global systems.
Leadership Perspectives on the Acquisition
According to Dr. Essam Hamza, chief executive of Treatment.com AI, the planned acquisition is a pivotal step in embedding conversational AI and mental health services more deeply into the company’s broader ecosystem. He noted that pairing Alea’s advanced platform with the Global Library of Medicine should help deliver a unified, personalized care experience while supporting expansion in fast-growing markets such as the Middle East. Dallala described the deal as strong validation of Alea’s mission to use AI and multimodal analysis to transform mental healthcare and highlighted plans to embed its tools directly into primary care pathways through Rocket Doctor AI’s infrastructure.
Transaction Structure and Financial Terms
Under the definitive agreement, Rocket Doctor AI will acquire all of Alea’s ordinary shares through a mix of cash, equity, and assumption of specific obligations. The company has already paid 15,000 United States dollars in cash and will issue 285,712 common shares to Alea shareholders at a deemed price of 0.70 Canadian dollars per share, subject to Canadian Securities Exchange pricing rules. In addition, Rocket Doctor AI has agreed to assume Alea’s obligations under a Simple Agreement for Future Equity, repaying the 180,000 dollar principal in equal monthly installments of 22,500 dollars until fully settled.
Conditions, Approvals, and Share Restrictions
Completion of the proposed transaction is contingent on several conditions, including execution of employment or consulting agreements with key Alea personnel and receipt of all necessary regulatory and third-party approvals. These approvals include clearance from the Canadian Securities Exchange and, if required, consent from Alea’s shareholders, and there is no assurance that all conditions will be satisfied or that closing will occur as contemplated. Securities issued in connection with the transaction will rely on prospectus exemptions under National Instrument 45-106 and will be subject to a four-month-and-one-day statutory hold period, while the consideration shares will also be placed in a 28-month escrow with 20 percent released every four months starting on the first anniversary of closing.
Corporate Relationship and Liability Profile
Rocket Doctor AI has confirmed that Alea and its shareholders are arm’s length parties to the company. No finder’s fees will be paid in relation to the proposed acquisition, underscoring a direct negotiation between the parties. The company will not assume any of Alea’s long-term liabilities other than the SAFE note, limiting the ongoing balance-sheet impact of the transaction.
About Rocket Doctor AI
Rocket Doctor AI develops physician-built, AI-enabled tools to support high-quality care across the full patient journey. Its core technology, the Global Library of Medicine, is a clinically validated decision support system created with input from hundreds of physicians worldwide. Alongside this sits Rocket Doctor Inc., an AI-powered digital health platform and marketplace that has enabled more than 300 medical doctors to deliver over 700,000 patient visits, helping clinicians launch virtual or hybrid practices, reduce administrative burden, and extend access to underserved, rural, and publicly insured populations in Canada and the United States.
The planned acquisition of Alea Health positions Rocket Doctor AI at the intersection of conversational AI, mental health, and global digital care delivery. By combining Alea’s technology, regional footprint, and specialist team with the Global Library of Medicine and existing virtual care infrastructure, the company aims to offer a more comprehensive and scalable healthcare solution. While the transaction remains subject to regulatory and contractual milestones, its successful completion would mark a significant step in Rocket Doctor AI’s strategy to modernize and globalize AI-driven healthcare.